

## **Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC**

**Leuven, BELGIUM – June 4, 2025 – 06:00 PM CET - [Oxurion NV](#)** (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received a transparency notification as follows:

Oxurion received a transparency notification on June 3, 2025, from Atlas Special Opportunities II, LLC indicating that as of May 30, 2025, it held 244,798 shares of the then outstanding 6,156,035 shares, and therefore crossed under the threshold (5%) by virtue of the selling of voting securities.

### **About Oxurion**

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. Oxurion is based in Leuven, Belgium. More information is available at [www.oxurion.com](http://www.oxurion.com).

### ***Important information about forward-looking statements***

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

### **For further information please contact:**

Oxurion NV
Pascal Ghoson
Chief Executive Officer
<a href="mailto:Pascal.ghoson@oxurion.com">Pascal.ghoson@oxurion.com</a>

---

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

## ANNEX 1

 <b>FINANCIAL SERVICES AND MARKETS AUTHORITY</b>	<b>Transparency notification</b> <b>Form TR-1 BE</b> <b>PART I</b>
--	--

### 1) Status of the notification

### 2) Issuer

Name	OXURION
Identification number	0881-620-924

### 3) Reason for the notification

[+]

### 4) Notification by

[+]

### 5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

[+]

### 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

[+]

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

### 7) Date on which the threshold is crossed

(DD/MM/YYYY)

### 8) Threshold that is crossed (in %)

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

### 9) Denominator

 Please enter the denominator before filling in the data

### 10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	609,382	244,798		3.98%	
<b>TOTAL</b>		<b>244,798</b>	<b>0</b>	<b>3.98%</b>	<b>0.00%</b>

[+]

 Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone".  
For groups, start with the ultimate controlling natural person or legal entity.  
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments		After the transaction				
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
<b>TOTAL</b>				<b>0</b>	<b>0.00%</b>	<b>+</b>

 **The totals** will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	<b>CALCULATE</b> 244,798	<b>3.98%</b>

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold /  0 voting rights as of  (DD/MM/YYYY)


13) Additional information

On 26 May 2025 (with settlement date on 28 May 2025), Atlas Special Opportunities II LLC sold 7,946 shares in Oxurion NV, as a result of which its shareholding decreased to 601,436 shares (= 9.77%, denominator = 6,156,035).  
 On 27 May 2025 (with settlement date on 29 May 2025), Atlas Special Opportunities II LLC sold 49,397 shares in Oxurion NV, as a result of which its shareholding decreased to 552,039 shares (= 8.97%, denominator = 6,156,035).  
 On 28 May 2025 (with settlement date on 30 May 2025), Atlas Special Opportunities II LLC sold 307,241 shares in Oxurion NV, as a result of which its shareholding decreased to 244,798 shares (= 3.98%, denominator = 6,156,035).

Done at  New York

On  02/06/2025 (DD/MM/YYYY)

Name & capacity  Patrick Vance, Proxyholder

Signature  Signed by:  
GAD24/99201472...

For security reasons, the unsigned form in **xlsx** format should be transmitted to [trp.fin@fma.be](mailto:trp.fin@fma.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.